HIV-Positive Children in Resource-Limited Setting Successfully Treated

Article

HOUSTON, Texas -- Clinicians have been able to reduce mortality rates in HIV positive children from 15 to 3 percent in the largest group of children treated with highly active antiretroviral therapy (HAART) in any single center worldwide, according to a paper published in the August 2004 issue of The Pediatric Infectious Disease Journal by researchers at Baylor College of Medicine in Houston.

   

The Baylor International Pediatric AIDS Initiative (BIPAI), the Municipal

Hospital Constanta (now the Infectious Diseases Hospital) and the Romanian

Ministry of Health and Family have worked collaboratively on a comprehensive

program of pediatric HIV/AIDS care and treatment since 1996 in an effort to

address the crisis in pediatric HIV in Romania. Through the end of 2002,

Romania had more than half of all European pediatric HIV/AIDS cases.  The

program is supported through a grant from the Abbott Laboratories Fund's Step

Forward Program.

   

"This is perhaps the first time that it has been demonstrated that HIV

positive children can be successfully treated with antiretroviral therapy in

resource-limited settings and the outcomes are comparable to those we have

seen in U.S. pediatric antiretroviral clinical trials," said Dr. Mark Kline,

program director of the Baylor International Pediatric AIDS Initiative.  "Few people

realize that Eastern Europe has the world's fastest growing HIV/AIDS epidemic,

and Romania is at its epicenter. Through our partnership with the Romanian

government and the Abbott Laboratories Fund, we have been able to build the

Romanian-American Children's Center and are now providing 620 children with

comprehensive care and treatment.  These children are not just surviving, but

thriving."

   

As of August 2003, a total of 452 children were receiving HAART, with 90

percent of children remaining on treatment after a follow-up period of

approximately 67 weeks. Daily hospital admissions declined from 30 in 2001 to

just 4 in 2003.  At the inception of therapy, more than half the children had

weights and heights that indicated severe growth failure.  After at least six

months on HAART, these same children experienced restoration of normal height

and weight growth.

   

"Unfortunately, children in the world's resource-limited countries are

often the last to receive health care," said Jeff Richardson, executive

director of Abbott Laboratories Fund's Step Forward program. "The BIPAI

Romania program shows that programs to treat children in these settings can

succeed and should be replicated.  Ideally, these findings will act as a

catalyst to increase the number of programs caring and treating HIV positive

children in the developing world."

   

Therapy for HIV-infected children living in the world's resource-limited

countries has been limited by not only financial resources, but also a lack of

infrastructure and human capacity for delivering HIV/AIDS care and treatment.

   

"The comprehensive program we implemented in Romania has been developed

deliberately, with careful consideration of the most efficient use of limited

resources," said Kline, also chief of retrovirology at Texas Children's

Hospital.  "These findings confirm that our Romanian model can be replicated

worldwide to provide care and treatment for children living with HIV/AIDS."

 

Source: Baylor College of Medicine

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content